These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38920720)

  • 21. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
    Flores I; Hevia D; Tittarelli A; Soto D; Rojas-Sepúlveda D; Pereda C; Tempio F; Fuentes C; Falcón-Beas C; Gatica J; Falcón-Beas F; Galindo M; Salazar-Onfray F; González FE; López MN
    J Immunol Res; 2019; 2019():9631515. PubMed ID: 31886313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
    Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
    Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Origin and Immune Recognition of Tumor-Specific Antigens.
    Apavaloaei A; Hardy MP; Thibault P; Perreault C
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
    Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
    J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
    Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
    Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
    Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G
    Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
    Meyer M; Parpoulas C; Barthélémy T; Becker JP; Charoentong P; Lyu Y; Börsig S; Bulbuc N; Tessmer C; Weinacht L; Ibberson D; Schmidt P; Pipkorn R; Eichmüller SB; Steinberger P; Lindner K; Poschke I; Platten M; Fröhling S; Riemer AB; Hassel JC; Roberti MP; Jäger D; Zörnig I; Momburg F
    Front Immunol; 2023; 14():1294565. PubMed ID: 38239352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of ABCB5 tumour antigen-specific CD8
    Borchers S; Maβlo C; Müller CA; Tahedl A; Volkind J; Nowak Y; Umansky V; Esterlechner J; Frank MH; Ganss C; Kluth MA; Utikal J
    Clin Exp Immunol; 2018 Jan; 191(1):74-83. PubMed ID: 28940439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.
    Fonteneau JF; Larsson M; Somersan S; Sanders C; Münz C; Kwok WW; Bhardwaj N; Jotereau F
    J Immunol Methods; 2001 Dec; 258(1-2):111-26. PubMed ID: 11684128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
    Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
    Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.
    Minati R; Perreault C; Thibault P
    Front Immunol; 2020; 11():583287. PubMed ID: 33424836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.
    Teck AT; Urban S; Quass P; Nelde A; Schuster H; Letsch A; Busse A; Walz JS; Keilholz U; Ochsenreither S
    Cancer Immunol Immunother; 2020 Jul; 69(7):1217-1227. PubMed ID: 32157447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
    Bai J; Wang J; Yang Y; Wang F; He A; Zhang W
    J Immunother; 2021 May; 44(4):141-150. PubMed ID: 33596023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
    Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
    Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.